Abstract

Psoriasis is a chronic inflammatory skin disease with an estimated worldwide prevalence of 0.5% to 11.4% in adults and up to 1.4% in children [1]. It is a disease characterized by erythematous, infiltrated, itchy and often painful skin lesions. Recent advances in the scientific community have enabled a greater understanding of the predisposing genetic factors, pathophysiology, comorbidities, and treatment of psoriasis. Currently available therapies for moderate-severe psoriasis (PASI [Psoriasis Area Severity Index] greater than 10) include DMARDs (Disease-modifying antirheumatic drugs)/conventional systemic drugs (cyclosporine, methotrexate [mtx] and acitretin) and systemic biological drugs, such as Tumor Necrosis Factor (TNF)-α inhibitors and Interleukin (IL) inhibitors.